PhRMA Named Eric Cantor President and CEO
The pharmaceutical industry group selected the former House majority leader to succeed outgoing head Steve Ubl.
Updated on Sept. 29, 2026 in People
Live Poll
Do you trust that pharmaceutical companies are pricing their prescription drugs fairly?
PhRMA has appointed Eric Cantor as its new president and CEO, tasking the former Virginia congressman with leading the biopharmaceutical industry advocacy group. He succeeds Steve Ubl, who served in the leadership role for 11 years before announcing his resignation.
Why it matters
Cantor brings extensive experience in federal policy and leadership to the organization at a pivotal time for the biopharmaceutical sector. His arrival coincides with heightened scrutiny from lawmakers regarding drug pricing and industry practices.
Eric Cantor, 63, takes over as president and CEO following the 11-year tenure of Steve Ubl. The transition occurs just weeks ahead of the November 2026 midterm elections.
The players
Eric Cantor
He is a former Republican U.S. congressman who represented the Richmond area of Virginia and served as House majority leader.
PhRMA
The Pharmaceutical Research and Manufacturers of America is a trade group representing the country's leading biopharmaceutical research companies.
Steve Ubl
He is the outgoing leader of PhRMA who oversaw the organization for over a decade before his departure.
The details
Cantor previously served in the U.S. House of Representatives from 2000 to 2014, including a stint as House majority leader from 2011 to 2014. Before joining PhRMA, he served as vice chair and managing director at Moelis & Company.
Timeline
Cantor represented Virginia in the U.S. House from 2000 to 2014.
He served as House majority leader from 2011 to 2014.
Steve Ubl announced his plan to step down in April 2026.
PhRMA announced Cantor as president and CEO on September 29, 2026.
The U.S. midterm elections are set for November 3, 2026.
Market Landscape
This leadership transition signals an aggressive move by the biopharmaceutical industry to bolster its lobbying presence in Washington. The appointment follows the established pattern of trade groups hiring former high-ranking officials to navigate the political shifts expected during the 2026 midterm election cycle.
Average consumers may see little immediate change, but industry lobbying shifts often influence future drug pricing legislation and healthcare access. This change in leadership could alter how pharmaceutical companies engage with federal regulators following the upcoming midterm elections.
The takeaway
Cantor is positioned to lead PhRMA through a period of potential political volatility as pharmaceutical oversight remains a central issue for lawmakers. Industry observers should track how his previous experience as a House majority leader influences the organization's legislative strategy.
What happens next
Democrats are expected to potentially take control of the House of Representatives following the midterm elections on November 3, 2026.
Further reading
For more on recent personnel shifts in major organizations, explore our People section.
Live Poll
Do you trust that pharmaceutical companies are pricing their prescription drugs fairly?
